These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 24062074)
21. Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease. Fukuda A; Wickman LT; Venkatareddy MP; Sato Y; Chowdhury MA; Wang SQ; Shedden KA; Dysko RC; Wiggins JE; Wiggins RC Kidney Int; 2012 Jan; 81(1):40-55. PubMed ID: 21937979 [TBL] [Abstract][Full Text] [Related]
22. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Zhang Y; Deb DK; Kong J; Ning G; Wang Y; Li G; Chen Y; Zhang Z; Strugnell S; Sabbagh Y; Arbeeny C; Li YC Am J Physiol Renal Physiol; 2009 Sep; 297(3):F791-801. PubMed ID: 19535571 [TBL] [Abstract][Full Text] [Related]
23. Regulation of podoplanin expression by microRNA-29b associates with its antiapoptotic effect in angiotensin II-induced injury of human podocytes. Eisenreich A; Langer S; Herlan L; Kreutz R J Hypertens; 2016 Feb; 34(2):323-31. PubMed ID: 26867059 [TBL] [Abstract][Full Text] [Related]
24. Effect of the knockdown of Cabin1 on p53 in glomerular podocyte. Wen Y; Zhou P; Liu L; Wang Z; Zhang Y; Liang J J Recept Signal Transduct Res; 2016; 36(2):173-80. PubMed ID: 26400065 [TBL] [Abstract][Full Text] [Related]
25. Reference genes for mesangial cell and podocyte qPCR gene expression studies under high-glucose and renin-angiotensin-system blocker conditions. Hosni ND; Anauate AC; Boim MA PLoS One; 2021; 16(7):e0246227. PubMed ID: 34242222 [TBL] [Abstract][Full Text] [Related]
26. eNOS deficiency predisposes podocytes to injury in diabetes. Yuen DA; Stead BE; Zhang Y; White KE; Kabir MG; Thai K; Advani SL; Connelly KA; Takano T; Zhu L; Cox AJ; Kelly DJ; Gibson IW; Takahashi T; Harris RC; Advani A J Am Soc Nephrol; 2012 Nov; 23(11):1810-23. PubMed ID: 22997257 [TBL] [Abstract][Full Text] [Related]
28. Unveiling Angiotensin II and Losartan-Induced Gene Regulatory Networks Using Human Urine-Derived Podocytes. Thimm C; Erichsen L; Wruck W; Adjaye J Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445727 [TBL] [Abstract][Full Text] [Related]
29. Podocyte-specific GLUT4-deficient mice have fewer and larger podocytes and are protected from diabetic nephropathy. Guzman J; Jauregui AN; Merscher-Gomez S; Maiguel D; Muresan C; Mitrofanova A; Diez-Sampedro A; Szust J; Yoo TH; Villarreal R; Pedigo C; Molano RD; Johnson K; Kahn B; Hartleben B; Huber TB; Saha J; Burke GW; Abel ED; Brosius FC; Fornoni A Diabetes; 2014 Feb; 63(2):701-14. PubMed ID: 24101677 [TBL] [Abstract][Full Text] [Related]
30. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. Naito T; Ma LJ; Yang H; Zuo Y; Tang Y; Han JY; Kon V; Fogo AB Am J Physiol Renal Physiol; 2010 Mar; 298(3):F683-91. PubMed ID: 20042458 [TBL] [Abstract][Full Text] [Related]
31. Angiotensin II receptor blocker attenuates intrarenal renin-angiotensin-system and podocyte injury in rats with myocardial infarction. Wen ZZ; Cai MY; Mai Z; Jin DM; Chen YX; Huang H; Geng DF; Wang JF PLoS One; 2013; 8(6):e67242. PubMed ID: 23799145 [TBL] [Abstract][Full Text] [Related]
32. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. Nishiyama A; Nakagawa T; Kobori H; Nagai Y; Okada N; Konishi Y; Morikawa T; Okumura M; Meda I; Kiyomoto H; Hosomi N; Mori T; Ito S; Imanishi M J Hypertens; 2008 Sep; 26(9):1849-59. PubMed ID: 18698221 [TBL] [Abstract][Full Text] [Related]
33. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Deb DK; Sun T; Wong KE; Zhang Z; Ning G; Zhang Y; Kong J; Shi H; Chang A; Li YC Kidney Int; 2010 Jun; 77(11):1000-9. PubMed ID: 20182412 [TBL] [Abstract][Full Text] [Related]
35. Renin-angiotensin system within the diabetic podocyte. Márquez E; Riera M; Pascual J; Soler MJ Am J Physiol Renal Physiol; 2015 Jan; 308(1):F1-10. PubMed ID: 25339703 [TBL] [Abstract][Full Text] [Related]
36. Podocytes as a target of prorenin in diabetes. Sakoda M; Itoh H; Ichihara A Curr Diabetes Rev; 2011 Jan; 7(1):17-21. PubMed ID: 21067509 [TBL] [Abstract][Full Text] [Related]
37. Activation of the Renin-Angiotensin System Disrupts the Cytoskeletal Architecture of Human Urine-Derived Podocytes. Erichsen L; Thimm C; Bohndorf M; Rahman MS; Wruck W; Adjaye J Cells; 2022 Mar; 11(7):. PubMed ID: 35406662 [TBL] [Abstract][Full Text] [Related]
38. High glucose and angiotensin II increase beta1 integrin and integrin-linked kinase synthesis in cultured mouse podocytes. Han SY; Kang YS; Jee YH; Han KH; Cha DR; Kang SW; Han DS Cell Tissue Res; 2006 Feb; 323(2):321-32. PubMed ID: 16189717 [TBL] [Abstract][Full Text] [Related]
39. Influence of tacrolimus on podocyte injury inducted by angiotensin II. Shengyou Y; Li Y; Zhihong H; Yuanyuan M J Renin Angiotensin Aldosterone Syst; 2015 Jun; 16(2):260-6. PubMed ID: 25650384 [TBL] [Abstract][Full Text] [Related]
40. Sparsentan improves glomerular hemodynamics, cell functions, and tissue repair in a mouse model of FSGS. Gyarmati G; Shroff UN; Izuhara A; Deepak S; Komers R; Bedard PW; Peti-Peterdi J JCI Insight; 2024 Sep; 9(19):. PubMed ID: 39226116 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]